Conexeu Sciences Inc.
CNXU
NASDAQ Capital Market16.84
USD
+2.72
- -
CIK
0002066836
ISIN
US20715F1003
CUSIP
20715F100
Return %
Stock
S&P500
1Y
28.84
26.53
3Y
28.84
76.60
5Y
28.84
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Miles Harrison
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 W Liberty St, Suite 880 Reno NV United States of America 89501
- IPO Date
- May 21, 2026
- CIK
- 0002066836
- Website
- conexeu.com
- Similar Companies
- Business
- Conexeu Sciences Inc. engages in the development and commercialization of regenerative biomaterials and tissue engineering solutions primarily for wound care, aesthetics, and soft tissue reconstruction. The company focuses on collagen-based technologies built around its CXU Scaffold Platform, a temperature-sensitive extracellular matrix scaffold that transitions to a gel-like state in vivo to support cell growth, tissue integration, and accelerated healing. Its flagship product developments include regenerative biomaterial solutions intended for skin regeneration, wound closure, and soft tissue augmentation, with applications spanning diabetic ulcers, acute and chronic wounds, dermal fillers, and aesthetic medicine indications. Headquartered in Paris, Île-de-France, France, Conexeu Sciences Inc. operates within the medical technology and regenerative medicine sectors, pursuing partnerships and collaborations to advance device-based therapies from research to pre-commercial and early-commercial stages. The company traces its origins to cellular therapy and regenerative medicine research programs and emphasizes a pathway through regulatory engagement and staged product development toward market entry. Its strategy centers on enabling physicians with scaffold-assisted tissue regeneration products designed to improve healing outcomes and reduce recovery times in both clinical and aesthetic settings. Latest major company changes include strategic partnerships and collaborations to advance CXU Scaffold technology through joint development and potential co-commercialization agreements; participation in regulatory discussions and designations as it progresses its device candidate through pre-market processes; and ongoing funding rounds and convertible securities transactions to support manufacturing process development, supplier qualification, regulatory strategy, and documentation rigor. The company has announced or engaged in initiatives related to expanding its commercial development program, including manufacturing process development and regulatory planning, in addition to pursuing strategic investments and equity offerings to support its growth trajectory. Industry positioning centers on regenerative medicine, wound care, aesthetics, and soft tissue reconstruction, with target markets comprising clinicians and patients requiring advanced wound therapies and cosmetic tissue restoration. The company’s product and service suite includes CXU Scaffold technology, scaffold-based regenerative therapies, liquid or gel-forming tissue substitutes, and related device development activities for skin regeneration and wound healing. Conexeu maintains an international footprint through development activities and potential commercial operations, with its core activities anchored in research, regulatory strategy, and early-stage manufacturing development to bring innovative regenerative solutions to the market.
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"